Index of artpub/2021/270201/

Papp, Kim A
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis : interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up
2021
https://ddd.uab.cat/record/270201